RCS - Physiomics PLC - IMC Presentation on Company Website

PhysiomicsAnnouncement

21/03/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240321:nRSU6677Ha&default-theme=true

RNS Number : 6677H  Physiomics PLC  21 March 2024

21 March 2024

 

Physiomics plc

("Physiomics" or "the Company")

 

IMC Presentation on Company Website

 

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science
company supporting the development of new therapeutics and personalised
medicine solutions, recently provided a brief update in-line with its interim
results via Investor Meet Company and has updated its website with the
presentation.

 

The presentation and Q&A from the meeting are now available at the
Company's website:

https://www.physiomics.co.uk/portfolio-item/investor-presentation-interim-results-and-company-update/
(https://www.physiomics.co.uk/portfolio-item/investor-presentation-interim-results-and-company-update/)

 

 

 

Enquiries:

 

Physiomics plc

Dr Jim Millen, Non-Executive Chairman, +44 (0)1235 841575

Dr Peter Sargent, Chief Executive Officer, +44 (0)1235 841575

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc combines cutting edge PKPD and QSP modelling and data science
techniques, along with deep biology expertise, to help biotech and pharma
companies streamline their drug development journeys.

 

Our approach is to derive insight from all relevant data in order to de-risk
decision making and optimise design research across discovery, pre-clinical
and clinical studies.

 

Through use of bespoke models and our proprietary Virtual Tumour technology,
the Physiomics team has informed the development of over 100 commercial
projects, over 50 targets and 75 drugs. Clients include Merck KGaA, Astellas,
Bicycle Therapeutics, Numab Therapeutics & CRUK.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEAKDEADPLEFA